Androgen deprivation therapy in locally advanced prostate cancer

被引：1

作者：

Rossi, D. ^{[3
]}

Beuzeboc, P. ^{[4
]}

Staerman, F. ^{[5
]}

Timsit, M. -O ^{[6
]}

El Fegoun, A. Benchikh ^{[1
,2
]}

机构：

[1] CHRU, Hop Huriez, Serv Urol, F-59037 Lille, France

[2] Hop Bichat Claude Bernard, Serv Urol, F-75018 Paris, France

[3] Hop Nord Marseille, Serv Urol, F-13915 Marseille 20, France

[4] Inst Curie, Med Oncol Serv, F-75248 Paris 05, France

[5] Hop Robert Debre, Serv Urol Androl, F-51092 Reims, France

[6] Hop Necker Enfants Malad, Serv Urol, F-75743 Paris 15, France

来源：

PROGRES EN UROLOGIE | 2010年 / 20卷

关键词：

Locally advanced prostate cancer; Androgen deprivation therapy; Castrate resistant prostate cancer; FLUTAMIDE; ADJUVANT; BICALUTAMIDE; RADIOTHERAPY; SUPPRESSION; CARCINOMA; ANTIGEN; METAANALYSIS; COMBINATION; MONOTHERAPY;

D O I：

10.1016/S1166-7087(10)70031-2

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

In case of biochemical recurrence after radical prostatectomy, hormonal treatments are equally efficient. Early hormonal treatment after biochemical recurrence reduces specific mortality, local and metastatic progression. In locally advanced prostate cancer, adjuvant radiation therapy after biochemical recurrence reduces local and metastatic recurrence. Withdrawal of the steroid hormone should be the first maneuver after primary hormonal therapy failure. Second generation anti-androgens (abiraterone and MDV 3100) should be released soon. These new hormonal agents are in clinical trials and show promising activity in patients with CRPC. (C) 2010 Published by Elsevier Masson SAS

引用

页码：S68 / S71

页数：4

共 25 条

[1]

Boccon-Gibod L, 2003, INT J CLIN PRACT, V57, P187

[2] Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial [J].

Bolla, M ;

Collette, L ;

Blank, L ;

Warde, P ;

Dubois, JB ;

Mirimanoff, RO ;

Storme, G ;

Bernier, J ;

Kuten, A ;

Sternberg, C ;

Mattelaer, J ;

Torecilla, JL ;

Pfeffer, JR ;

Cutajar, CL ;

Zurlo, A ;

Pierart, M .

LANCET, 2002, 360 (9327) :103-108

[3] Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials [J].

Boustead, Gregory ;

Edwards, Steven J. .

BJU INTERNATIONAL, 2007, 99 (06) :1383-1389

[4] Is the flare phenomenon clinically significant? [J].

Bubley, GJ .

UROLOGY, 2001, 58 (2A) :5-9

[5] Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological Group [J].

Calais da Silva, Fernando E. C. ;

Bono, Aldo V. ;

Whelan, Peter ;

Brausi, Maurizio ;

Marques Queimadelos, Anton ;

Portillo Martin, Jose A. ;

Kirkali, Ziya ;

Calais da Silva, Fernando M. V. ;

Robertson, Chris .

EUROPEAN UROLOGY, 2009, 55 (06) :1269-1277

[6] Adjuvant radiotherapy for patients with locally advanced prostate cancer - A new standard? [J].

Ganswindt, Ute ;

Stenzl, Arnulf ;

Bamberg, Michael ;

Belka, Claus .

EUROPEAN UROLOGY, 2008, 54 (03) :528-542

[7] High dose bicalutamide for androgen independent prostate cancer: Effect of prior hormonal therapy [J].

Joyce, R ;

Fenton, MA ;

Rode, P ;

Constantine, M ;

Gaynes, L ;

Kolvenbag, G ;

DeWolf, W ;

Balk, S ;

Taplin, ME ;

Bubley, GJ .

JOURNAL OF UROLOGY, 1998, 159 (01) :149-153

[8] Androgen-deprivation therapy as primary treatment for localized prostate cancer - Data from cancer of the prostate strategic urologic research endeavor (CaPSURE) [J].

Kawakami, J ;

Cowan, JE ;

Elkin, EP ;

Latini, DM ;

DuChane, J ;

Carroll, PR .

CANCER, 2006, 106 (08) :1708-1714

[9]

KELLY WK, 1993, J UROLOGY, V149, P607

[10]

Kirby R, 1999, PROSTATE, V40, P105

← 1 2 3 →